The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Analytical methods for physicochemical characterization of antibody drug conjugates
Open accessAbstract
Antibody-drug conjugates (ADCs), formed through the chemical linkage of a potent small molecule cytotoxin (drug) to a monoclonal antibody, have more complex and heterogeneous structures than the corresponding antibodies. This review describes the analytical methods that have been used in their physicochemical characterization. The selection of the most appropriate methods for a specific ADC is heavily dependent on the properties of the linker, the drug, and the choice of attachment sites (lysines, inter-chain cysteines, Fc glycans). Improvements in analytical techniques such as protein mass spectrometry and capillary electrophoresis have significantly increased the quality of information that can be obtained for use in product and process characterization, and for routine lot release and stability testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationBrentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Identification of multiple sources of charge heterogeneity in a recombinant antibody
Harris, R. J., Kabakoff, B., Macchi, F. D., Shen, F. J., Kwong, M., Andya, J. D., Shire, S. J., Bjork, N., Totpal, K., & Chen, A. B. (2001) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00548-x · Cited by 500
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Khawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0987 · Cited by 292
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
Vlasak, J., & Ionescu, R. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786402 · Cited by 260
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy
Chari, R. V. J. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00095-1 · Cited by 235
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Willner, D., Trail, P. A., Hofstead, S. J., King, H. D., Lasch, S. J., Braslawsky, G. R., Greenfield, R. S., Kaneko, T., & Firestone, R. A. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00024a015 · Cited by 225
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Wakankar, A. A., Feeney, M. B., Rivera, J., Chen, Y., Kim, M., Sharma, V. K., & Wang, Y. J. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900434c · Cited by 195
Self-citationNon-enzymatic hinge region fragmentation of antibodies in solution
Cordoba, A. J., Shyong, B.-J., Breen, D., & Harris, R. J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.12.033 · Cited by 188
Greenfield, R. S., Kaneko, T., Daues, A., Edson, M. A., Fitzgerald, K. A., Olech, L. J., Grattan, J. A., Spitalny, G. L., & Braslawsky, G. R. (1990) · PubMed · Cited by 179
Lazar, A. C., Wang, L., Blättler, W. A., Amphlett, G. W., Lambert, J. M., & Zhang, W. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1987 · Cited by 155
Hunt, G. E., & Nashabeh, W. (1999) · Analytical Chemistry · doi:10.1021/ac981209m · Cited by 154
King, D., Dubowchik, G. M., Mastalerz, H. A., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., & Trail, P. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020149g · Cited by 135
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y., & Damle, N. K. (2007) · Leukemia · doi:10.1038/sj.leu.2404866 · Cited by 134
Laguzza, B. C., Nichols, C. L., Briggs, S., et al. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00123a007 · Cited by 128
Assessing monoclonal antibody product quality attribute criticality through clinical studies
Goetze, A. M., Schenauer, M. R., & Flynn, G. C. (2010) · mAbs · doi:10.4161/mabs.2.5.12897 · Cited by 105
CHARI, R. V. J., Jackel, K. A., Bourret, L. A., et al. (1995) · PubMed · Cited by 99
Sosic, Z., Houde, D. J., Blum, A., Carlage, T., & Lyubarskaya, Y. V. (2008) · Electrophoresis · doi:10.1002/elps.200800157 · Cited by 92
Stéphan, J.-P., Chan, P., Lee, C., Nelson, C., Elliott, J. M., Bechtel, C., Raab, H. E., Xie, D., Akutagawa, J., Baudys, J., et al. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800059t · Cited by 83
Self-citationHollander, I. J., Kunz, A., & Hamann, P. R. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700321z · Cited by 80
Safavy, A., Bonner, J. A., Waksal, H. W., Buchsbaum, D. J., Gillespie, G. Y., Khazaeli, M. B., Arani, R. B., Chen, D., Carpenter, M., & Raisch, K. P. (2003) · Bioconjugate Chemistry · doi:10.1021/bc020033z · Cited by 77
Progress in immunoconjugate cancer therapeutics
Payne, G. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00057-6 · Cited by 76
Quality by design for biopharmaceuticals : principles and case studies
Rathore, A. S., & Mhatre, R. (2009) · Cited by 73
Quiles, S., Raisch, K. P., Sanford, L. L., Bonner, J. A., & Safavy, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900899g · Cited by 70
Siegel, M. M., Tabei, K., Kunz, A., et al. (1997) · Analytical Chemistry · doi:10.1021/ac970035q · Cited by 65
Perspectives on Anti-HER Monoclonal Antibodies
Ranson, M., & Sliwkowski, M. X. (2002) · Oncology · doi:10.1159/000066203 · Cited by 63
Stan, A. C., Radu, D. L., Casares, S. A., Bona, C. A., & Brumeanu, T. (1999) · PubMed · Cited by 55
Fleming, M. S., Zhang, W., Lambert, J. M., & Amphlett, G. W. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.02.010 · Cited by 23
Cited by
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
Metadata
- Authors
- Wakankar, A., Chen, Y., Gokarn, Y., & Jacobson, F. S.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2011-03
- Volume
- 3
- Issue
- 2
- Pages
- 161-172
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2073176225
- Cited by
- 382
- References
- 45
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.